CytomX Therapeutics, Inc. (NASDAQ:CTMX) will release its fourth-quarter earnings before the opening bell on Monday, March 16.
Analysts expect the South San Francisco, California-based company to report loss of 9 cents per share, versus a year-ago profit of 23 cents per share . The consensus estimate for CytomX Therapeutics’ quarterly revenue is $7.33 million (it reported $38.09 million last year), according to Benzinga Pro.
On Nov. 6, CytomX Therapeutics reported worse-than-expected third-quarter financial results.
Shares of CytomX Therapeutics fell 3.9% to close at $4.68 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the …
This post was originally published here
